In response to Fitch maintaining Hong Kong's AA- credit rating and stable outlook, the Hong Kong Special Administrative ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...

In related news, Singapore-based pharmaceutical company Mirxes, which specializes in cancer treatment, also had a strong debut in Hong Kong on the same day. The company’s shares rose by 28% in morning ...

Singapore-based cancer diagnostics firm MiRXES has listed on the Hong Kong Stock Exchange, with shares jumping 24.5% above the HKD 23.3 offer price on debut. The stock was trading at HKD 30 as of 3:00 ...

Theodore Shou, CEO of Yiyi Capital, discusses the recent strong performance of the IPO market in Hong Kong and says that the valuation premium between mainland China and Hong Kong stocks would narrow ...

The Chinese drugmaker raised HK$9.74 billion, equivalent to US$1.25 billion, in net proceeds, making it one of Hong Kong's largest IPOs so far this year. The stock was priced at HK$44.05 per share, ...

Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Robin Zeng’s high-stakes bets—from quitting his first job to founding CATL—have reshaped the global EV battery market.

For years, Dominari Holdings’ shifting priorities and tribulations remained largely out of the spotlight. That changed when ...

ONE of the assumed pressure points in the ongoing nonviolent dispute between the United States and China is the latter's ...

(Yicai) May 22 -- Initial public offerings on the Hong Kong stock exchange surged almost four-fold in value in the past year, ...

As CapitaLand Investment celebrates 25 years as a listed stock, market watchers are wondering whether The Ascott could be ...